Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Featured Clinical Focus
AMLBiomarker-Driven Lung CancerBone Marrow & SCTBTK Inhibitors: In-FocusCAR T-Cell TherapyChronic Lymphocytic LeukemiaEGFR-Positive Lung CancerEndometrial CancerFollicular LymphomaHCCLung CancerMantle Cell LymphomaMPNsMultiple MyelomaRenal Cell CarcinomaSmall Cell Lung CancerThyroid Cancers
Clinical Focus
View MoreBrain CancerBreast CancerGastrointestinal CancerGenitourinary CancersGynecologic CancersHead & Neck CancersHematologyLeukemiasLung CancerLymphomasMelanomaSarcomaSkin CancersThyroid Cancers
NEWS
All NewsClinical FocusSpecial Reports
CONFERENCES
Conference CoverageConference Listing
MEDIA
All VideosCase-Based Peer PerspectivesExpert Perspective Virtual Tumor BoardInterviewsInvestigator PerspectivesMedical World NewsPodcastsPrecision Medicine
PUBLICATIONS
All PublicationsEvolving ParadigmsRoundtable Meetings SpotlightTargeted Therapies in Oncology
CME/CE
RESOURCES
Case-Based Roundtable SeriesClinical TrialsPartnersPrecision Medicine PerspectivesPress ReleasesSponsored ContentTreatment Resources
SUBSCRIBE
eNewsletter
  • About Us
  • Advertise
  • Contact Us
  • CureToday.com
  • CancerNetwork.com
  • OncLive.com
  • OncNursingNews.com
  • Do Not Sell My Information
  • Privacy
  • Terms & Conditions
  • MJHLS Brand Logo

© 2023 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.

Advertisement
Featured Clinical Focus
  • AML
  • Biomarker-Driven Lung Cancer
  • Bone Marrow & SCT
  • BTK Inhibitors: In-Focus
  • CAR T-Cell Therapy
  • Chronic Lymphocytic Leukemia
  • EGFR-Positive Lung Cancer
  • Endometrial Cancer
  • Follicular Lymphoma
  • HCC
  • Lung Cancer
  • Mantle Cell Lymphoma
  • MPNs
  • Multiple Myeloma
  • Renal Cell Carcinoma
  • Small Cell Lung Cancer
  • Thyroid Cancers
Clinical FocusSee All >
  • Brain Cancer
  • Breast Cancer
  • Gastrointestinal Cancer
  • Genitourinary Cancers
  • Gynecologic Cancers
  • Head & Neck Cancers
  • Hematology
  • Leukemias
  • Lung Cancer
  • Lymphomas
  • Melanoma
  • Sarcoma
  • Skin Cancers
  • Thyroid Cancers
baltimore conference logo
  • About Us
  • Advertise
  • Contact Us
  • CureToday.com
  • CancerNetwork.com
  • OncLive.com
  • OncNursingNews.com
  • Do Not Sell My Information
  • Privacy
  • Terms & Conditions
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.

A 54-Year-Old Woman with ER+/PR+ Breast Cancer

EP. 1: Introduction: A 54-Year-Old Woman With ER+/PR+ Breast Cancer

February 4th 2022

Lowell Hart, MD, FACP, introduces our patient case, a 54-year-old woman with ER+/PR+ breast cancer, and discusses his strategy and the risk of recurrence for the disease.

EP. 2: Adjuvant Therapy Options for HR+ Breast Cancer

February 4th 2022

Dr Hart explains the different adjuvant therapy options for patients with HR+ breast cancer.

EP. 3: CDK4/6 Inhibitor Breast Cancer Clinical Trials

February 4th 2022

Dr Hart delves into the CDK4/6 inhibitor clinical trials for breast cancer, some that he’s even participated in.

EP. 4: Common Adverse Events With CDK4/6 Inhibitors

February 4th 2022

Lowell Hart, MD, FACP, lists the different types of adverse events that are common when CDK4/6 inhibitors are used in both the adjuvant and advanced cancer setting.

EP. 5: Case Patient Prognosis

February 4th 2022

Dr Hart explains his prognosis for our case patient.

EP. 6: ER+ Early Breast Cancer Future Directions and A Note on Ki-67 Analyses

February 4th 2022

Lowell Hart, MD, FACP, discusses what he’d like to see in the future for the treatment of ER+ breast cancer and includes a note concerning Ki-67 analyses.

Advertisement
Advertisement